title: 2010 position paper of the Italian Society of Hypertension (SIIA): angiotensin receptor blockers and risk of cancer.
abstract: Antihypertensive therapy has been demonstrated to significantly reduce cardiovascular and non-cardiovascular mortality in randomized controlled clinical trials. In the past, however, doubts have been raised on the safety of one class of blood pressure lowering drugs, namely the angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]), in terms of increased risk of myocardial infarction. Several comprehensive meta-analyses have definitely demonstrated no significant increased risk of myocardial infarction in patients treated with ARBs compared with placebo or any other active treatments. More recently, a partial meta-analysis has suggested a potential link between the use of this drug class and an increased risk of cancer. Although a further comprehensive network meta-analysis demonstrated the lack of any increased risk of cancer development or cancer mortality in patients treated with different antihypertensive drug classes, including ARBs, compared with placebo, this report has generated claims and uncertainties in the medical community and produced a vast echo in the lay press. The biological plausibility, the potential pathophysiological mechanisms, and the clinical evidence that rule out such hypotheses are discussed here. The present article, which represents a position paper of the Italian Society of Hypertension (SIIA), states that the benefits derived from the use of ARBs outweigh the potential risks, and that the use of these drugs should be maintained according to present indications.
authors: Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy. massimo.volpe@uniroma1.it
authors: Massimo
authors: M
authors: Volpe
authors: Alberto
authors: A
authors: Morganti
references: J Cancer Res Clin Oncol. 2009 Oct;135(10):1429-35
references: 19399518
references: Lancet Oncol. 2011 Jan;12(1):65-82
references: 21123111
references: Am Surg. 2007 Mar;73(3):230-8
references: 17375777
references: Lancet. 2003 Sep 6;362(9386):759-66
references: 13678868
references: BMC Cancer. 2010 Feb 24;10:67
references: 20181281
references: Lancet. 1998 Jul 18;352(9123):179-84
references: 9683206
references: J Gastroenterol Hepatol. 2007 Apr;22(4):577-84
references: 17376054
references: Int J Clin Oncol. 2005 Dec;10(6):405-10
references: 16369744
references: Cancer Biol Ther. 2010 Feb;9(4):277-85
references: 20026904
references: Hypertension. 2010 Feb;55(2):516-22
references: 20026759
references: J Hypertens. 2007 Sep;25(9):1751-62
references: 17762635
references: J Hypertens. 2009 May;27(5):941-6
references: 19381108
references: J Clin Invest. 2003 Jul;112(1):67-75
references: 12840060
references: Carcinogenesis. 2005 Feb;26(2):271-9
references: 15637093
references: J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S36-43
references: 16565245
references: Clin Exp Pharmacol Physiol. 2001 Dec;28(12):1066-9
references: 11903317
references: Lancet Oncol. 2010 Jul;11(7):627-36
references: 20542468
references: J Hypertens. 2011 Apr;29(4):623-35
references: 21358417
references: Lancet. 2004 Jun 19;363(9426):2022-31
references: 15207952
references: Anticancer Res. 2008 Sep-Oct;28(5A):2813-7
references: 19035315
references: Science. 2010 Jan 22;327(5964):459-63
references: 20093472
references: J Hypertens. 2008 Apr;26(4):819-24
references: 18327094
references: Eur Heart J. 2011 Jan;32(1):19-22
references: 20965885
references: BMJ. 2004 Nov 27;329(7477):1248-9
references: 15564232